212 related articles for article (PubMed ID: 15983047)
1. Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library.
Yusa K; Maeda Y; Fujioka A; Monde K; Harada S
J Biol Chem; 2005 Aug; 280(34):30083-90. PubMed ID: 15983047
[TBL] [Abstract][Full Text] [Related]
2. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan.
Platt EJ; Shea DM; Rose PP; Kabat D
J Virol; 2005 Apr; 79(7):4357-68. PubMed ID: 15767436
[TBL] [Abstract][Full Text] [Related]
3. Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.
Yuan Y; Yokoyama M; Maeda Y; Terasawa H; Harada S; Sato H; Yusa K
PLoS One; 2013; 8(6):e65115. PubMed ID: 23840315
[TBL] [Abstract][Full Text] [Related]
4. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
Platt EJ; Durnin JP; Kabat D
J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
[TBL] [Abstract][Full Text] [Related]
6. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.
Platt EJ; Kuhmann SE; Rose PP; Kabat D
J Virol; 2001 Dec; 75(24):12266-78. PubMed ID: 11711617
[TBL] [Abstract][Full Text] [Related]
7. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
[TBL] [Abstract][Full Text] [Related]
8. Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropism.
Kato K; Sato H; Takebe Y
J Virol; 1999 Jul; 73(7):5520-6. PubMed ID: 10364300
[TBL] [Abstract][Full Text] [Related]
9. A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc.
Yuan Y; Maeda Y; Terasawa H; Monde K; Harada S; Yusa K
Virology; 2011 May; 413(2):293-9. PubMed ID: 21440278
[TBL] [Abstract][Full Text] [Related]
10. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
Kuhmann SE; Pugach P; Kunstman KJ; Taylor J; Stanfield RL; Snyder A; Strizki JM; Riley J; Baroudy BM; Wilson IA; Korber BT; Wolinsky SM; Moore JP
J Virol; 2004 Mar; 78(6):2790-807. PubMed ID: 14990699
[TBL] [Abstract][Full Text] [Related]
11. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.
Dragic T; Trkola A; Thompson DA; Cormier EG; Kajumo FA; Maxwell E; Lin SW; Ying W; Smith SO; Sakmar TP; Moore JP
Proc Natl Acad Sci U S A; 2000 May; 97(10):5639-44. PubMed ID: 10779565
[TBL] [Abstract][Full Text] [Related]
12. Altered sensitivity of an R5X4 HIV-1 strain 89.6 to coreceptor inhibitors by a single amino acid substitution in the V3 region of gp120.
Maeda Y; Yusa K; Harada S
Antiviral Res; 2008 Feb; 77(2):128-35. PubMed ID: 18160142
[TBL] [Abstract][Full Text] [Related]
13. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
Verrier F; Borman AM; Brand D; Girard M
AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
[TBL] [Abstract][Full Text] [Related]
14. Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5.
Armand-Ugón M; Moncunill G; Gonzalez E; Mena M; Ballana E; Clotet B; Esté JA
J Antimicrob Chemother; 2010 Mar; 65(3):417-24. PubMed ID: 20067983
[TBL] [Abstract][Full Text] [Related]
15. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.
Cormier EG; Dragic T
J Virol; 2002 Sep; 76(17):8953-7. PubMed ID: 12163614
[TBL] [Abstract][Full Text] [Related]
16. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
[TBL] [Abstract][Full Text] [Related]
17. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
18. Effect of lysine to arginine mutagenesis in the V3 loop of HIV-1 gp120 on viral entry efficiency and neutralization.
Schwalbe B; Schreiber M
PLoS One; 2015; 10(3):e0119879. PubMed ID: 25785610
[TBL] [Abstract][Full Text] [Related]
19. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
Henrich TJ; Tsibris AM; Lewine NR; Konstantinidis I; Leopold KE; Sagar M; Kuritzkes DR
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):420-7. PubMed ID: 20856130
[TBL] [Abstract][Full Text] [Related]
20. Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.
Kuwata T; Enomoto I; Baba M; Matsushita S
Antimicrob Agents Chemother; 2016 Jan; 60(1):437-50. PubMed ID: 26525792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]